myasthenia gravis
MeSH: D009157ORPHA: 5891 Treatment Available
Overview
human disease
Available Treatments (1)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| efgartigimod alfa Orphan Cold Chain | Intravenous infusion, 400mg/20mL solution | FDA Approved (2021), EMA Approved (2022), Japan Approved (2022) | 6 | 14d |
Clinical Presentation
Signs and symptoms associated with myasthenia gravis, sourced from HPO and Orphanet clinical annotations.
Raynaud phenomenonThymomaAnti-Lrp4 antibody positivityPsychosisAcrocyanosisSeizureHemolytic anemiaHepatitisPure red cell aplasiaMuscle weaknessPtosisOphthalmoparesisDiplopiaAbnormal thymus morphologyDysarthriaBulbar palsyDysphoniaDysphagiaDyspneaSkeletal muscle atrophyDifficulty climbing stairsLimb muscle weaknessThymus hyperplasiaFatigueSingle fiber EMG abnormalityFatigable weakness of skeletal musclesAnti-neuromuscular Junction acetylcholine receptor antibody positivityAnti-muscle-specific tyrosine kinase antibodyWeakness of facial musculatureMyositisAnti-titin antibody positivityAnti-ryanodine receptor antibodyAnti-Kv1.4 antibodyAnti-DCC netrin 1 receptor antibody positivityHearing impairmentHyperthyroidismHashimoto thyroiditisRheumatoid arthritisSystemic lupus erythematosusRespiratory failureGlycosuriaParesthesiaPrimary adrenal insufficiencyHyperacusisTongue atrophy
Classification & Codes
MeSH Code
D009157Orphanet Code
ORPHA:589myasthenia gravis
| MeSH | D009157 |
| Orphanet | ORPHA:589 |
| Treatments | 1 drug(s) |
| Symptoms on record | 45 signs |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO